CD274 and neoplasm: Atezolizumab is approved in Europe as a first-line therapy in metastatic NSCLC with no EGFR or ALK aberrations (a) in tumours with a high (≥50%) PD-L1 status or ≥10% tumour-infiltrating cells; (b) as a combinational therapy with nab paclitaxel and carboplatin in non-squamous tumours; or (c) as a combinational therapy with bevacizumab, paclitaxel, or carboplatin in non-squamous tumours.